Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum.

Trial Profile

Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Tumour cell vaccine-GVAX (Primary) ; Celecoxib; Cyclophosphamide
  • Indications Cancer metastases; Epithelial dysplasia; Germ cell and embryonal neoplasms; Malignant melanoma; Sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 10 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top